144 related articles for article (PubMed ID: 17412873)
1. Antigenicity testing by immunohistochemistry after tissue oxidation.
Blind C; Koepenik A; Pacyna-Gengelbach M; Fernahl G; Deutschmann N; Dietel M; Krenn V; Petersen I
J Clin Pathol; 2008 Jan; 61(1):79-83. PubMed ID: 17412873
[TBL] [Abstract][Full Text] [Related]
2. Loss of antigenicity in stored sections of breast cancer tissue microarrays.
Fergenbaum JH; Garcia-Closas M; Hewitt SM; Lissowska J; Sakoda LC; Sherman ME
Cancer Epidemiol Biomarkers Prev; 2004 Apr; 13(4):667-72. PubMed ID: 15066936
[TBL] [Abstract][Full Text] [Related]
3. [Antigen retrieval: its significance and drawbacks in immunohistochemistry].
Ezaki T
Kaibogaku Zasshi; 1996 Dec; 71(6):615-28. PubMed ID: 9038004
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of seven oestrogen receptor beta antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissue.
Skliris GP; Parkes AT; Limer JL; Burdall SE; Carder PJ; Speirs V
J Pathol; 2002 Jun; 197(2):155-62. PubMed ID: 12015738
[TBL] [Abstract][Full Text] [Related]
5. Optimal fixation conditions for immunocytochemical analysis of estrogen receptor in cytologic specimens of breast carcinoma.
Gong Y; Symmans WF; Krishnamurthy S; Patel S; Sneige N
Cancer; 2004 Feb; 102(1):34-40. PubMed ID: 14968416
[TBL] [Abstract][Full Text] [Related]
6. Surgical specimen can be replaced by core samples in assessment of ER, PR and HER-2 for invasive breast cancer.
Sutela A; Vanninen R; Sudah M; Berg M; Kiviniemi V; Rummukainen J; Kataja V; Kärjä V
Acta Oncol; 2008; 47(1):38-46. PubMed ID: 17851859
[TBL] [Abstract][Full Text] [Related]
7. Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma.
Goldstein NS; Ferkowicz M; Odish E; Mani A; Hastah F
Am J Clin Pathol; 2003 Jul; 120(1):86-92. PubMed ID: 12866377
[TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
[TBL] [Abstract][Full Text] [Related]
9. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical markers in urinary bladder carcinomas from paraffin-embedded archival tissue after storage for 5-70 years.
Litlekalsoy J; Vatne V; Hostmark JG; Laerum OD
BJU Int; 2007 May; 99(5):1013-9. PubMed ID: 17437436
[TBL] [Abstract][Full Text] [Related]
11. Tissue microarrays compared with whole sections and biochemical analyses. A subgroup analysis of DBCG 82 b&c.
Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Andersen J; Overgaard J
Acta Oncol; 2008; 47(4):591-9. PubMed ID: 18465327
[TBL] [Abstract][Full Text] [Related]
12. Long-term preservation of antigenicity on tissue microarrays.
DiVito KA; Charette LA; Rimm DL; Camp RL
Lab Invest; 2004 Aug; 84(8):1071-8. PubMed ID: 15195116
[TBL] [Abstract][Full Text] [Related]
13. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.
Brouckaert O; Pintens S; Van Belle V; Van Huffel S; Camerlynck E; Amant F; Leunen K; Smeets A; Berteloot P; Van Limbergen E; Decock J; Hendrickx W; Weltens C; Van den Bogaert W; Vanden Bempt I; Drijkoningen M; Paridaens R; Wildiers H; Vergote I; Christiaens MR; Neven P
Breast Cancer Res Treat; 2009 May; 115(2):349-58. PubMed ID: 18629635
[TBL] [Abstract][Full Text] [Related]
14. Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1.
Pintens S; Neven P; Drijkoningen M; Van Belle V; Moerman P; Christiaens MR; Smeets A; Wildiers H; Vanden Bempt I
J Clin Pathol; 2009 Jul; 62(7):624-8. PubMed ID: 19561231
[TBL] [Abstract][Full Text] [Related]
15. Ancillary p16(INK4a) adds no meaningful value to the performance of ER/PR/Vim/CEA panel in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray study.
Yao CC; Kok LF; Lee MY; Wang PH; Wu TS; Tyan YS; Cheng YW; Kung MF; Han CP
Arch Gynecol Obstet; 2009 Sep; 280(3):405-13. PubMed ID: 19153755
[TBL] [Abstract][Full Text] [Related]
16. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer.
Tischkowitz M; Brunet JS; Bégin LR; Huntsman DG; Cheang MC; Akslen LA; Nielsen TO; Foulkes WD
BMC Cancer; 2007 Jul; 7():134. PubMed ID: 17650314
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen in breast disease.
Poh BH; Jayaram G; Sthaneshwar P; Yip CH
Malays J Pathol; 2008 Jun; 30(1):43-51. PubMed ID: 19108411
[TBL] [Abstract][Full Text] [Related]
18. Zinc presence in invasive ductal carcinoma of the breast and its correlation with oestrogen receptor status.
Farquharson MJ; Al-Ebraheem A; Geraki K; Leek R; Jubb A; Harris AL
Phys Med Biol; 2009 Jul; 54(13):4213-23. PubMed ID: 19521003
[TBL] [Abstract][Full Text] [Related]
19. Rabbit monoclonal antibodies show higher sensitivity than mouse monoclonals for estrogen and progesterone receptor evaluation in breast cancer by immunohistochemistry.
Rocha R; Nunes C; Rocha G; Oliveira F; Sanches F; Gobbi H
Pathol Res Pract; 2008; 204(9):655-62. PubMed ID: 18565685
[TBL] [Abstract][Full Text] [Related]
20. Utility of cytology microarray constructed from effusion cell blocks for immunomarker validation.
Pu RT; Giordano TJ; Michael CW
Cancer; 2008 Oct; 114(5):300-6. PubMed ID: 18798226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
